Caliper's New Quantum FX microCT for Preclinical Lung Cancer Imaging Studies Selected by NCI
Adoption by leading government laboratory highlights Caliper's expansion into anatomical preclinical imaging solutions that complement the company's optical molecular imaging offerings
HOPKINTON, Mass., September 22, 2010 -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a
leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute (NCI) has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.
The selection of the Quantum FX by the NCI validates the need for a low-radiation dose
microCT imaging system. Unlike traditional microCT systems that use higher dose radiation, the Quantum FX allows longitudinal studies and provides more accurate, detailed, and clinically relevant data, throughout the drug discovery and development process. This approach, which has broad utility in the research space, is critical to fully understand the progression of lung cancer, as well as the efficacy of chemotherapeutic agents. Furthermore, the images captured on the Quantum FX can be co-registered with other imaging modalities, providing a more complete picture of disease. The Quantum FX is a critical tool to support the preclinical development of
better targeted and safer therapies for the millions of patients suffering from lung cancer.
"The NCI is world-renowned for its commitment to advancing oncology research, and its
decision to use the Quantum FX for lung cancer-related studies indicates the critical value of Caliper's preclinical imaging technology," said Kevin Hrusovsky, President and Chief Executive Officer of Caliper Life Sciences. "The Quantum FX is Caliper's foray into the microCT market and key to our strategy to address the larger $500M preclinical market. Caliper is committed to building out the company's in vitro-to-in vivo-to-human bridge by providing researchers with the tools needed to translate medical research from the early preclinical stage into the clinic."
Non-invasive imaging is critical to monitoring disease progression and therapeutic efficacy in preclinical drug development studies. Caliper's IVIS imaging systems have earned recognition worldwide as enabling and innovative research tools for non-invasive preclinical research.
Nearly 900 IVIS systems are in use in drug discovery and life science research laboratories and over 1,500 peer-reviewed research articles attest to their value in a wide spectrum of therapeutic areas.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation &
liquid handling, optical imaging technologies, and discovery & development outsourcing
solutions. For more information please visit www.caliperLS.com.
Media Contact:
Benjamin Navon/Kristin Villiotte
Schwartz Communications
781.684.0770
caliper@schwartz-pr.com
